drugset / Trial / NCT05820685

Dronabinol On the Pain Experience

NCT05820685

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to identify the effect dronabinol has on opioid exposure when used as an adjunct to the current standard multi-modal pain regimen (MMPR)

Timeline

Start
2023-07-27
Primary completion
2024-04-29
Completion
2024-04-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Dronabinol Other / unclassified 10 mg
Background Acetaminophen Small molecule 1000 mg
Background Gabapentin Small molecule 300 mg
Background Naproxen Small molecule 500 mg
Background Oxycodone Other / unclassified 5 mg
Background Tramadol Other / unclassified 50 mg

Indications